⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 3, 2024Open Access

Figure S4 from Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases

Christina A. Von Roemeling Bently P. Doonan Kelena Klippel Daniel Schultz Lan Hoang-Minh Vrunda Trivedi Chenglong Li Rylynn A. Russell Raju S. Kanumuri Abhisheak Sharma Han W. Tun Duane A. Mitchell

View Full Paper

Ask AI

Bookmark

Share

Abstract

Supplemental Figure 4. CA-4948 viability assessment in A20 and B16F10 cancer cells.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Roemeling et al. (2024) studied this question.

synapsesocial.com/papers/68e709f1b6db6435876834f1 https://doi.org/10.1158/1078-0432.25537730

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S5 from Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases2024
2Figure S6 from Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases2024
3Figure S3 from Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases2024
4Figure S1 from Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases2024
5Figure S8 from Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases2024

Figure S7 from Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases2024
Data from Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases2024
Abstract 2902: CA-4948 (emavusertib) improves treatment response of preclinical metastatic brain melanoma to anti-PD-1 immune checkpoint blockade2024